ArticleInfection and drug resistance2025
Predictors of Serological Cure in Syphilis Patients: A Retrospective Study at a Tertiary Hospital in Bandung, Indonesia.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Syphilis is an infection caused by the spirochete Purpose: This study aims to determine the factors associated with the serological cure of syphilis at Dr Hasan Sadikin General Hospital Bandung, Indonesia. Material and Methods: The study procedures were carried out using a retrospective descriptive method. Secondary data were obtained from medical records at the Dermatology and Venereology Outpatient Clinic of Hasan Sadikin Hospital, Bandung, Indonesia, from 1 January 2018 to 31 December 2022. Results: The sample population comprised 266 cases of syphilis, consisting of 185 male and 81 female patients. The bivariate analysis results showed that patients aged less than 35 years had a serological cure rate of 75.4%, with a 3.89 times higher chance of achieving serological cure compared to those ≥35 years (p < 0.0001, OR = 3.89, 95% CI 1.85-8.13). In addition, the proportion of serological cure was higher in patients with Venereal disease research laboratory test (VDRL) titers of ≤1:8 before therapy (OR = 0.61, 95% CI 0.28-1.35, P = 0.226). Similar results were also obtained in those with HIV-negative (OR = 0.83, 9% CI 0.38-1.81, P=0.648), and benzathine penicillin G therapy (OR = Reff, P = 0.226). Conclusion: An age of <35 years was a highly influential factor in the success of syphilis therapy. This indicates that intervention and monitoring strategies should focus on this age group, especially in resource-limited settings. The most common time for serological cure in early syphilis was the 9
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.